Wegovy Can Help Reduce Heart Failure Symptoms Even When People Don't Lose as Much Weight
Semaglutide, a GLP-1 receptor agonist used in diabetes and weight-loss drugs, shows heart-related benefits beyond weight loss, improving symptoms and physical limitations in heart failure patients with preserved ejection fraction and type 2 diabetes. The study highlights semaglutide's potential mechanisms beyond weight loss, including effects on inflammation and insulin resistance.
Reference News
Semaglutide, a GLP-1 receptor agonist used in diabetes and weight-loss drugs, shows heart-related benefits beyond weight loss, improving symptoms and physical limitations in heart failure patients with preserved ejection fraction and type 2 diabetes. The study highlights semaglutide's potential mechanisms beyond weight loss, including effects on inflammation and insulin resistance.